Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
Phathom Pharmaceuticals (NASDAQ: PHAT) has issued a clarification regarding a Schedule 13D filing by Frazier Life Sciences. The company emphasized that the upcoming filing includes only administrative changes to the reporting approach and does not represent any reduction in Frazier's ownership position in Phathom.
While the updated filing may show different breakouts of holdings between funds and persons, and changes in warrant treatment may affect certain percentage calculations, these modifications are purely administrative in nature. The company confirms that no actual sale of shares has occurred.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha fornito chiarimenti riguardo a una Schedule 13D presentata da Frazier Life Sciences. L'azienda ha sottolineato che la prossima dichiarazione riguarda esclusivamente modifiche amministrative al modo di rendicontare e non implica alcuna riduzione della partecipazione di Frazier in Phathom.
Sebbene il documento aggiornato possa mostrare suddivisioni diverse delle partecipazioni tra fondi e persone, e il trattamento delle warrant possa influenzare alcuni calcoli percentuali, tali variazioni sono di natura puramente amministrativa. La società conferma che non è stata effettuata alcuna vendita effettiva di azioni.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha emitido una aclaración sobre una presentación Schedule 13D por parte de Frazier Life Sciences. La empresa enfatizó que la próxima presentación incluye únicamente cambios administrativos en la forma de reportar y no representa ninguna reducción en la participación de Frazier en Phathom.
Aunque la declaración actualizada puede mostrar diferentes desgloses de participaciones entre fondos y personas, y el tratamiento de los warrants puede afectar ciertos cálculos porcentuales, estas modificaciones son puramente administrativas. La compañía confirma que no se ha producido ninguna venta real de acciones.
Phathom Pharmaceuticals (NASDAQ: PHAT)는 Frazier Life Sciences의 Schedule 13D 제출에 대해 설명을 내놓았습니다. 회사는 이번 제출이 보고 방식의 행정적 변경만을 포함하며 Frazier의 Phathom 지분 감소를 의미하지 않는다고 강조했습니다.
업데이트된 제출서에는 펀드와 개인 간 보유 내역의 구분이 달라 보일 수 있고, 워런트 처리 방식이 일부 비율 계산에 영향을 줄 수 있으나 이러한 변경은 모두 행정적 성격에 불과합니다. 회사는 실제 주식 매각은 없었다고 확인했습니다.
Phathom Pharmaceuticals (NASDAQ: PHAT) a publié une clarification concernant un dépôt Schedule 13D par Frazier Life Sciences. La société précise que le prochain dépôt comporte uniquement des modifications administratives de la manière de déclarer et ne représente aucune réduction de la participation de Frazier dans Phathom.
Si le dossier mis à jour peut montrer des répartitions différentes des participations entre fonds et personnes, et si le traitement des warrants peut affecter certains calculs en pourcentage, ces modifications sont purement administratives. La société confirme qu'aucune vente effective d'actions n'a eu lieu.
Phathom Pharmaceuticals (NASDAQ: PHAT) hat eine Klarstellung zu einer Schedule‑13D‑Einreichung von Frazier Life Sciences veröffentlicht. Das Unternehmen betonte, dass die bevorstehende Einreichung lediglich administrative Änderungen in der Berichterstattung enthält und keine Verringerung von Fraziers Beteiligung an Phathom darstellt.
Die aktualisierte Einreichung kann zwar andere Aufschlüsselungen der Bestände zwischen Fonds und Personen zeigen und eine geänderte Behandlung von Warrants bestimmte Prozentberechnungen beeinflussen, diese Anpassungen sind jedoch rein administrativer Natur. Das Unternehmen bestätigt, dass kein tatsächlicher Verkauf von Aktien stattgefunden hat.
- None.
- None.
Insights
Phathom clarifies no change in Frazier's ownership stake despite reporting changes in upcoming 13D filing.
Phathom Pharmaceuticals has issued an important clarification regarding an upcoming Schedule 13D filing by its lead shareholder, Frazier Life Sciences. The company explicitly states that the filing does not represent any reduction in Frazier's ownership position in Phathom, despite what the numbers might suggest.
This type of proactive communication is significant for investors who track institutional ownership. Schedule 13D filings are required when an entity owns more than 5% of a public company, and changes in these filings often trigger investor reactions. The clarification explains that while the breakout of holdings between funds and persons may appear different than in previous filings, and the treatment of warrants may reduce certain percentages, these differences stem solely from administrative changes in Frazier's reporting approach.
This announcement reflects sound investor relations practice by preemptively addressing potential misinterpretations of regulatory filings. Large shareholders reducing positions can sometimes signal reduced confidence in a company's prospects, so Phathom is acting to prevent any unwarranted market reaction by providing context before the filing becomes public. For a biopharmaceutical company commercializing novel treatments for gastrointestinal diseases, maintaining the appearance of stable institutional support is particularly important for investor confidence.
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.
While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
What changes were announced in Frazier Life Sciences' 13D filing for Phathom Pharmaceuticals (PHAT)?
Has Frazier Life Sciences reduced its stake in Phathom Pharmaceuticals (PHAT)?
What products does Phathom Pharmaceuticals (PHAT) currently market?
When will the updated Schedule 13D filing for PHAT be submitted?
